# CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

> **NCT04136171** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 1438 (actual)

## Conditions studied

- Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

## Interventions

- **DRUG:** Eplontersen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04136171
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-13
- **Primary completion:** 2026-04
- **Final completion:** 2026-08
- **Target enrollment:** 1438 (ACTUAL)
- **Last updated:** 2025-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04136171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04136171, "CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04136171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*